ArticleAnnals of biomedical engineering2017
Controlled and Sequential Delivery of Fluorophores from 3D Printed Alginate-PLGA Tubes.
Article in Annals of biomedical engineering, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- 3D printing for sustainable water treatment: innovations, applications, and future perspectives.RSC advances · 2026Review
- An updated review on application of 3D printing in fabricating pharmaceutical dosage forms.Drug delivery and translational research · 2022Review
- Advances in three-dimensional bioprinted stem cell-based tissue engineering for cardiovascular regeneration.Journal of molecular and cellular cardiology · 2022Review
- Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- 3D Coaxial Bioprinting: Process Mechanisms, Bioinks and Applications.Progress in biomedical engineering (Bristol, England) · 2022Article
- Polysaccharide 3D Printing for Drug Delivery Applications.Pharmaceutics · 2022Review
- Expanding sacrificially printed microfluidic channel-embedded paper devices for construction of volumetric tissue models in vitro.Biofabrication · 2020Article
- Recent Trends in Three-Dimensional Bioinks Based on Alginate for Biomedical Applications.Materials (Basel, Switzerland) · 2020Review
- 3D printing in drug delivery systems.Journal of 3D printing in medicine · 2019Article
- Tissue Engineering Strategies for Intervertebral Disc Treatment Using Functional Polymers.Polymers · 2019Review
- Bioinks and bioprinting technologies to make heterogeneous and biomimetic tissue constructs.Materials today. Bio · 2019Review
- Controlled drug delivery from 3D printed two-photon polymerized poly(ethylene glycol) dimethacrylate devices.International journal of pharmaceutics · 2018Article
- Nanogels for Pharmaceutical and Biomedical Applications and Their Fabrication Using 3D Printing Technologies.Materials (Basel, Switzerland) · 2018Review
- Bioprinted Osteogenic and Vasculogenic Patterns for Engineering 3D Bone Tissue.Advanced healthcare materials · 2017Article
- Bone Regeneration Using Gene-Activated Matrices.The AAPS journal · 2017Review
- 3D Bioprinting for Organ Regeneration.Advanced healthcare materials · 2017Review
- Current status of three-dimensional printing inks for soft tissue regeneration.Tissue engineering and regenerative medicine · 2016Review
- Innovative bioinks for 3D bioprinting: Exploring technological potential and regulatory challenges.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Controlled drug delivery systems, that include sequential and/or sustained drug delivery, have been utilized to enhance the therapeutic effects of many current drugs by effectively delivering drugs in a time-dependent and repeatable manner. In this study, with the aid of 3D printing technology, a novel drug delivery device was fabricated and tested to evaluate sequential delivery functionality. With an alginate shell and a poly(lactic-co-glycolic acid) (PLGA) core, the fabricated tubes displayed sequential release of distinct fluorescent dyes and showed no cytotoxicity when incubated with the human embryonic kidney (HEK293) cell line or bone marrow stromal stem cells (BMSC). The controlled differential release of drugs or proteins through such a delivery system has the potential to be used in a wide variety of biomedical applications from treating cancer to regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.